Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Business Wire•16/11/2026•07:00 ET
0
Key Highlights
- ➤Faeth will sponsor Phase 1b/2 PIKTOR-giredestrant breast cancer study.
- ➤Roche will supply investigational giredestrant for Faeth’s combination study.
- ➤Faeth retains all rights to PIKTOR under the agreement.
- ➤PIKTOR combines serabelisib and sapanisertib to inhibit multiple pathway nodes.
- ➤Interim breast cancer data is anticipated in 2027.
Expert Statements
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“Endocrine therapy remains the backbone of treatment in HR+/HER2- breast cancer, and resistance driven by the PI3K/AKT/mTOR pathway is one of the central problems in this setting”
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“We believe PIKTOR’s multi-node approach to this pathway is well suited to patients whose disease has progressed on prior endocrine therapy, and this study will allow us to evaluate that approach in combination with giredestrant and potentially CDK4/6 regimens.”
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Faeth will sponsor and conduct a Phase 1b/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant
Get started
Create a free account to read the full story.
